• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, July 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Inhaled receptor decoy therapy for COVID-19 in preclinical models

Bioengineer by Bioengineer
August 30, 2023
in Health
Reading Time: 7 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The surface protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as the spike protein, is critical for infecting host cells. The spike protein facilitates the infection process by binding to angiotensin-converting enzyme 2 (ACE2) receptors on the surface of airway epithelial cells, initiating the virus entry into the cells. By engineering an ACE2 receptor to increase the affinity to the spike protein, researchers demonstrated a novel method to neutralize the virus effectively. The engineered ACE2 (3N39v4-Fc) acts as a decoy by binding to the viral spike protein, thus preventing the binding of viruses to the ACE2 receptor on the cell surface. This inhibition by the ACE2 decoy is detrimental to SARS-CoV-2.

Inhaled Receptor Decoys: Efficacy Against SARS-CoV-2 in Monkey Preclinical Models

Credit: Toru Okamoto, Juntendo University

The surface protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as the spike protein, is critical for infecting host cells. The spike protein facilitates the infection process by binding to angiotensin-converting enzyme 2 (ACE2) receptors on the surface of airway epithelial cells, initiating the virus entry into the cells. By engineering an ACE2 receptor to increase the affinity to the spike protein, researchers demonstrated a novel method to neutralize the virus effectively. The engineered ACE2 (3N39v4-Fc) acts as a decoy by binding to the viral spike protein, thus preventing the binding of viruses to the ACE2 receptor on the cell surface. This inhibition by the ACE2 decoy is detrimental to SARS-CoV-2.

 

The study was carried out by a team of researchers led by Professor Toru Okamoto from the Department of Microbiology at Juntendo University. While the team, including Prof. Okamoto, Dr. Atsushi Hoshino from the Department of Cardiovascular Medicine at Kyoto Prefectural University of Medicine, and Prof. Junichi Takagi from the Laboratory of Protein Synthesis and Expression at Osaka University demonstrated that 3N39v4-Fc had a 100-times higher binding affinity to the spike protein compared to unmodified (wild-type) ACE2. This highlighted the potency of 3N39v4-Fc to prevent the emergence of resistant virus and the efficacy in rodent models in 2021 and 2022.

 

In the latest study published in the journal Science Translational Medicine, the team demonstrated the potency of the engineered ACE2 receptor decoy (3N39v4-Fc) against the Omicron variants, including BA.2.12.1, BA.2.75, and the currently spreading XBB and BQ.1. While several groups are working on the development of an ACE2 decoy, the team, for the very first time, reported a therapeutic effect of the 3N39v4-Fc in a preclinical model using cynomolgus monkeys. The team investigated several effects in the model, including the antiviral effect, changes in CT images in the chest, inflammation, pharmacokinetics of the 3N39v4-Fc, and safety. These findings of the study contribute to further evaluation in human trials.

 

First, the team tested the effectiveness of the 3N39v4-Fc in preventing the emergence of escape mutants, 3N39v4-Fc-resistant viruses that evade the ACE2 receptor decoys. Although the team’s earlier study demonstrated the ability of an engineered ACE2 decoy to prevent the emergence of escape mutants, in the latest study, the team validated and confirmed their results using advanced techniques. Their experiments revealed that the 3N39v4-Fc reduced the possibility of the escape mutants more efficiently than wild-type ACE2, demonstrating a minimum risk of the emergence of escape mutants by high-affinization!

 

 

Further, the team tested the feasibility of the 3N39v4-Fc administration via the inhalation route, as compared with the administration via the intravenous injection route used in the team’s earlier study. Through advanced imaging techniques based on positron emission tomography (PET) imaging and zirconium (Zr)-labeling, the team found that the distribution and clearance patterns within the body differed between inhalation and intravenous administration route in rodents. Intravenous administration resulted in a predominant accumulation of 3N39v4-Fc in the liver, whereas inhalation led to uptake predominantly in the lungs. Remarkably, inhalation administration demonstrated a significant dose-sparing benefit of up to 20-fold compared to conventional intravenous administration. “This comparison holds immense significance, as it achieves equivalent therapeutic results with just a twentieth of the intravenous dose, potentially leading to substantial cost reduction in treatment against respiratory infections,” explains Prof. Okamoto.

 

Again, to verify the potential efficacy of these results for humans, the researchers conducted experiments on cynomolgus monkeys infected with the Delta variant of SARS-CoV-2. The effect of 3N39v4-Fc was tested by both intravenous and inhalation routes. The treatment led to a reduction in lung abnormalities and a substantial reduction in infectious virus levels, showing its potential as a therapeutic option.

 

“Our successful treatment of SARS-CoV-2-infected cynomolgus monkeys emphasizes the efficacy and safety of this novel drug. The exceptional efficacy via inhalation administration of the decoys presents a groundbreaking approach to reduce the strain on healthcare systems as it enables patients to self-administer the drug,” says Prof. Okamoto.

 

In conclusion, the engineered ACE2 decoy exhibits potent neutralizing activity against SARS-CoV-2 variants, and the remarkable efficacy in monkeys highlights its potential for application in the treatment of humans.

 

 

 

Reference

 

Authors

 

 

 

 

 

 

 

 

 

Emiko Urano1, Yumi Itoh2,3, Tatsuya Suzuki2,3, Takanori Sasaki4, Jun-ichi Kishikawa5, Kanako Akamatsu6, Yusuke Higuchi7, Yusuke Sakai8, Tomotaka Okamura1, Shuya Mitoma9, Fuminori Sugihara10, Akira Takada2, Mari Kimura2, Shuto Nakao2, Mika Hirose5, Tadahiro Sasaki11, Ritsuko Koketsu11, Shunya Tsuji12, Shota Yanagida13, Tatsuo Shioda11,14, Eiji Hara12,14, Satoaki Matoba7, Yoshiharu Matsuura14, Yasunari Kanda13, Hisashi Arase14,15,16, Masato Okada6,14,15,17, Junichi Takagi14,18, Takayuki Kato5,14,16, Atsushi Hoshino7, Yasuhiro Yasutomi1,19, Akatsuki Saito9,20,21, Toru Okamoto2,3,14

Title of the original paper An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models

Journal

Science Translational Medicine

DOI

 

Affiliations

10.1126/scitranslmed.adi2623

 

1Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tsukuba, Japan.

2Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

3Department of Microbiology, Juntendo University School of Medicine, Japan

4Collaborative Research Center for Okayama Medical Innovation Center, Dentistry, and Pharmaceutical Sciences, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.

5Laboratory of CryoEM Structural Biology, Institute for Protein Research, Osaka University, Osaka, Japan.

6Department of Oncogene, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

7Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

8Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

9Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Japan.

10Central Instrumentation Laboratory, Research Institute for Microbial Diseases, Osaka University, Japan.

11Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Japan.

12Department of Molecular Microbiology, Research Institute for Microbial Diseases, Osaka University, Japan.

13Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan.

14Center for Infectious Disease Education and Research, Osaka University, Japan.

15Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Japan.

16Center for Advanced Modalities and Drug Delivery System, Osaka University, Japan.

17Laboratory of Oncogene research, World Premier International Immunology Frontier Research Centre, Osaka University, Japan.

18Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Japan.

19Department of Molecular and Experimental Medicine, Mie University Graduate School of Medicine, Japan.

20Center for Animal Disease Control, University of Miyazaki, Japan.

21Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Japan

Youtube Link https://youtu.be/sgxH57cHIfI

 



Journal

Science Translational Medicine

DOI

10.1126/scitranslmed.adi2623

Method of Research

Experimental study

Subject of Research

Animals

Article Title

An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models

Article Publication Date

30-Aug-2023

COI Statement

A.H., S.M., J.T., and T. Okamoto. are inventors on a patent filed by Kyoto Prefectural University of Medicine and Osaka University (ACE2 mutant protein, PCT/JP2021/031372). All other authors declare that they have no competing interests.

Share12Tweet8Share2ShareShareShare2

Related Posts

Single-Cell Atlas Links Chemokines to Type 2 Diabetes

July 20, 2025
blank

AI Diagnoses Structural Heart Disease via ECG

July 17, 2025

Functional Regimes Shape Soil Microbiome Response

July 17, 2025

Stealth Adaptations in Large Ichthyosaur Flippers

July 17, 2025

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    63 shares
    Share 25 Tweet 16
  • USF Research Unveils AI Technology for Detecting Early PTSD Indicators in Youth Through Facial Analysis

    43 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • New Measurements Elevate Hubble Tension to a Critical Crisis

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Additive Manufacturing of Monolithic Gyroidal Solid Oxide Cells

Machine Learning Uncovers Sorghum’s Complex Mold Resistance

Pathology Multiplexing Revolutionizes Disease Mapping

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.